Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
Current Oncology (Toronto, Ont.)|October 28, 2025
From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter TransformationMathias Castonguay, Marie-France Gagnon, Alexandre Le Nguyen, et al.
Current Oncology (Toronto, Ont.)|November 26, 2024
A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell TransplantRichard LeBlanc, Stéphanie Thiant, Rafik Terra, et al.
Journal of Virology|June 26, 2015
Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFLRajnish Kumar, Ruimin Pan, Chitra Upadhyay, et al.
Bone Marrow Transplantation|June 9, 2026
Risk factors for EBV reactivation and impact of graft composition following GVHD prophylaxis with rabbit ATG or PTCyStéphanie Thiant, Simon Dufresne, Imran Ahmad, et al.
Blood Advances|July 19, 2023
Improved outcomes of UM171-expanded cord blood transplantation compared with other graft sources: real-world evidenceSandra Cohen, Nadia Bambace, Imran Ahmad, et al.
Virology|July 29, 2010
Structure-guided design and immunological characterization of immunogens presenting the HIV-1 gp120 V3 loop on a CTB scaffoldMaxim Totrov, Xunqing Jiang, Xiang-Peng Kong, et al.
British Journal of Haematology|May 29, 2019
Allodepleted T-cell immunotherapy after haploidentical haematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxisDenis Claude Roy, Sylvie Lachance, Sandra Cohen, et al.
Transplantation and Cellular Therapy|October 17, 2024
A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma PatientsJean Roy, Sandra Cohen, Guy Sauvageau, et al.
Transplantation and Cellular Therapy|December 26, 2021
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian PerspectiveOlivier Veilleux, Jean-Sébastien Claveau, Habiba Alaoui, et al.
Cytotherapy|March 20, 2023
International Society for Cell & Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplantMoises Garcia-Rosa, Allistair Abraham, Alice Bertaina, et al.
Pageof 8